Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Parallel-group Study of the Safety and Efficacy of RO4917523 Versus Placebo, as Adjunctive Therapy in Patients With Major Depressive Disorder With Inadequate Response to Ongoing Antidepressant Treatment
Brief Summary: This randomized, double-blind, placebo-controlled, parallel group study will evaluate the safety and efficacy of RO4917523 as adjunctive therapy in patients with major depressive disorder and an inadequate response to ongoing antidepressant therapy. Anticipated time on study treatment is 6 weeks with a 3-week follow-up.


Options:
A: Arm Label: Intravenous Ketamine; Type: EXPERIMENTAL; Interventions: Drug: Intravenous Ketamine | Arm Label: Electroconvulsive Therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Electroconvulsive Therapy | Intervention Type: DRUG; Name: Intravenous Ketamine; Assigned to Arm(s): Intravenous Ketamine | Intervention Type: PROCEDURE; Name: Electroconvulsive Therapy; Assigned to Arm(s): Electroconvulsive Therapy
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: RO4917523 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: RO4917523 0.5 mg | Arm Label: RO4917523 1.5 mg; Type: EXPERIMENTAL; Interventions: Drug: RO4917523 1.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: RO4917523 0.5 mg; Assigned to Arm(s): RO4917523 0.5 mg | Intervention Type: DRUG; Name: RO4917523 1.5 mg; Assigned to Arm(s): RO4917523 1.5 mg
C: Arm Label: Intranasal Esketamine 84mg plus Oral Antidepressant; Type: EXPERIMENTAL; Interventions: Drug: Esketamine, Drug: Duloxetine (Oral Antidepressant), Drug: Escitalopram (Oral antidepressant), Drug: Sertraline (Oral Antidepressant), Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant) | Arm Label: Esketamine 56 mg plus Oral Antidepressant; Type: EXPERIMENTAL; Interventions: Drug: Esketamine, Drug: Duloxetine (Oral Antidepressant), Drug: Escitalopram (Oral antidepressant), Drug: Sertraline (Oral Antidepressant), Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant) | Arm Label: Placebo plus Oral Antidepressant; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: Duloxetine (Oral Antidepressant), Drug: Escitalopram (Oral antidepressant), Drug: Sertraline (Oral Antidepressant), Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant) | Intervention Type: DRUG; Name: Esketamine; Assigned to Arm(s): Esketamine 56 mg plus Oral Antidepressant, Intranasal Esketamine 84mg plus Oral Antidepressant | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo plus Oral Antidepressant | Intervention Type: DRUG; Name: Duloxetine (Oral Antidepressant); Assigned to Arm(s): Esketamine 56 mg plus Oral Antidepressant, Intranasal Esketamine 84mg plus Oral Antidepressant, Placebo plus Oral Antidepressant | Intervention Type: DRUG; Name: Escitalopram (Oral antidepressant); Assigned to Arm(s): Esketamine 56 mg plus Oral Antidepressant, Intranasal Esketamine 84mg plus Oral Antidepressant, Placebo plus Oral Antidepressant | Intervention Type: DRUG; Name: Sertraline (Oral Antidepressant); Assigned to Arm(s): Esketamine 56 mg plus Oral Antidepressant, Intranasal Esketamine 84mg plus Oral Antidepressant, Placebo plus Oral Antidepressant | Intervention Type: DRUG; Name: Venlafaxine Extended Release (XR) (Oral Antidepressant); Assigned to Arm(s): Esketamine 56 mg plus Oral Antidepressant, Intranasal Esketamine 84mg plus Oral Antidepressant, Placebo plus Oral Antidepressant
D: Arm Label: IV normal saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: IV normal saline | Arm Label: IV GLYX-13; Type: EXPERIMENTAL; Interventions: Drug: GLYX-13 | Arm Label: SC GLYX-13; Type: EXPERIMENTAL; Interventions: Drug: GLYX-13 | Intervention Type: DRUG; Name: GLYX-13; Assigned to Arm(s): IV GLYX-13, SC GLYX-13 | Intervention Type: DRUG; Name: IV normal saline; Assigned to Arm(s): IV normal saline

Answer: B